Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PRALATREXATE INJECTION safely and effectively. See full prescribing information for PRALATREXATE INJECTION. PRALATREXATE injection, for intravenous use Initial U.S. Approval: 2009
Medication labelWhy this: Advisory · dailymed-prescription
Pralatrexate injection is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- pralatrexate
- product_names
- Pralatrexate
- ndc
- 43598-342, 43598-343, 43598-342-11, 43598-343-23
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en